Abstract
(-)-Stepholidine (SPD), a natural product isolated from the Chinese herb Stephania, possesses dopamine (DA) D1 partial agonistic and D2 antagonistic properties in the nigrostriatal and mesocorticolimbic DAergic pathways. These unique dual effects have suggested that SPD can effectively restore previously imbalanced functional linkage between D1 and D2 receptors under schizophrenic conditions, in which, SPD improves both the negative and positive symptoms of schizophrenia. SPD also relieves the motor symptoms of Parkinsons disease (PD) when co-administered with Levodopa. Furthermore, SPD exhibits neuroprotective effects through an antioxidative mechanism and slows down the progression of neuronal degeneration in the substantia nigra (SN) of PD patients and/or animal models. Therefore, SPD is a novel, natural compound with potentially therapeutic roles in the treatment of schizophrenia and/or PD.
Keywords: Stepholidine, dopamine D1 receptor, dopamine D2 receptor, schizophrenia, Parkinson's disease
Current Neuropharmacology
Title: The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Volume: 5 Issue: 4
Author(s): Kechun Yang, Guozhang Jin and Jie Wu
Affiliation:
Keywords: Stepholidine, dopamine D1 receptor, dopamine D2 receptor, schizophrenia, Parkinson's disease
Abstract: (-)-Stepholidine (SPD), a natural product isolated from the Chinese herb Stephania, possesses dopamine (DA) D1 partial agonistic and D2 antagonistic properties in the nigrostriatal and mesocorticolimbic DAergic pathways. These unique dual effects have suggested that SPD can effectively restore previously imbalanced functional linkage between D1 and D2 receptors under schizophrenic conditions, in which, SPD improves both the negative and positive symptoms of schizophrenia. SPD also relieves the motor symptoms of Parkinsons disease (PD) when co-administered with Levodopa. Furthermore, SPD exhibits neuroprotective effects through an antioxidative mechanism and slows down the progression of neuronal degeneration in the substantia nigra (SN) of PD patients and/or animal models. Therefore, SPD is a novel, natural compound with potentially therapeutic roles in the treatment of schizophrenia and/or PD.
Export Options
About this article
Cite this article as:
Yang Kechun, Jin Guozhang and Wu Jie, The Neuropharmacology of (-)-Stepholidine and its Potential Applications, Current Neuropharmacology 2007; 5 (4) . https://dx.doi.org/10.2174/157015907782793649
DOI https://dx.doi.org/10.2174/157015907782793649 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology PET Imaging in Parkinsons Disease
Current Medical Imaging Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain
CNS & Neurological Disorders - Drug Targets Going up in Smoke? A Review of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia
Current Pharmaceutical Design Review of Recent Patents on Detection and Quantification of Tremor
Recent Patents on Biomedical Engineering (Discontinued) Subject Index to Volume 4
Current Topics in Medicinal Chemistry Regulation of Postsynaptic Stability by the L-type Calcium Channel Ca<sub>V</sub>1.3 and its Interaction with PDZ Proteins
Current Molecular Pharmacology Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Design and Synthesis of Dopaminergic Agonists
Current Medicinal Chemistry Neuroimaging Studies of Substance Abuse in Schizophrenia
Current Psychiatry Reviews 5-HT2 Receptors
Current Drug Targets - CNS & Neurological Disorders Road to Future: iPSC Clinical Application in Parkinson’s Disease Treatment
Current Molecular Medicine Neurotoxicity: The Broad Framework of Electron Transfer, Oxidative Stress and Protection by Antioxidants
Current Medicinal Chemistry - Central Nervous System Agents Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
CNS & Neurological Disorders - Drug Targets Ion Channel Defects in Idiopathic Epilepsies
Current Pharmaceutical Design Recent Advances in the Development of 14-Alkoxy Substituted Morphinans as Potent and Safer Opioid Analgesics
Current Medicinal Chemistry Risk Factors and Metabolism of Different Brain Regions by Positron Emission Tomography in Parkinson Disease with Disabling Dyskinesia
Current Neurovascular Research A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Current Pharmaceutical Design